Three weeks after FDA approved Amgen Inc.'s biosimilar to Genentech Inc.'s Avastin (bevacizumab), the companies have launched opposing suits against each other. Amgen is seeking a declaratory judgment that its product Mvasi (bevacizumab-awwb) does not infringe 27 patents related to Avastin while Genentech is claiming infringement.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?